Please assess the completion status of the following clinical trial:

Trial Title: Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects for whom the investigator believes that parents/guardians can and will comply with the requirements of the protocol.~* A male or female between, and including, 6 and 12 weeks of age (+ 6 days) at the time of the first vaccination.~* Written informed consent obtained from the parent or guardian of the subject.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~* Born after 36 weeks gestation.~* For inclusion in the booster phase, subjects must have received all three doses in the primary phase.~Exclusion Criteria:~Exclusion criteria for enrolment (primary phase)~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs since birth.~* Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of study vaccine(s).~* Previous vaccination against Neisseria meningitidis, Haemophilus influenzae type b, diphtheria, tetanus, pertussis, and/or poliovirus; more than one previous dose of hepatitis B vaccine.~* History of Neisseria meningitidis, hepatitis B, Haemophilus influenzae type b, diphtheria, tetanus, polio or pertussis diseases.~* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccines, or by dry natural latex rubber.~* Major congenital defects or serious chronic illness.~* History of any neurologic disorders or seizures.~* Acute disease at time of enrollment.~* Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.~* Concurrent participation in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).~Exclusion criteria for enrolment (booster phase)~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding entry into the booster phase (Visit 4), or planned use during the study period.~* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs since birth.~* Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days of entry into the booster phase (Visit 4) with the exception of Prevnar® and Hib (see the following three criteria) (Note; licensed influenza vaccine is allowed throughout the study)~* Planned administration/administration of a fourth dose of Prevnar® within 30 days of a booster dose of Infanrix®~* Previous administration of a booster dose of Hib prior to entry to the booster phase.~* Previous administration of a primary dose of Hib vaccine that is not part of the study protocol.~* Previous vaccination against Neisseria meningitidis that is not part of the study protocol.~* Previous vaccination with diphtheria, tetanus and pertussis antigens outside of the primary phase of the study.~* History of Neisseria meningitidis, Hib, diphtheria, tetanus or pertussis diseases.~* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccines, or by dry natural latex rubber.~* Major congenital defects or serious chronic illness.~* History of any neurologic disorders or seizures.~* Acute disease at time of enrollment.~* Administration of immunoglobulins and/or any blood products within the past 3 months or planned administration during the study period.~* Concurrent participation in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- Menhibrix 1 Group (Type: EXPERIMENTAL): Subjects received 3 doses of Menhibrix vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age during the Primary Vaccination Phase. For the Booster Vaccination Phase, subjects were re-randomized and received either 1 dose of Nimenrix vaccine (at 12-15 months of age) and 1 dose of Infanrix vaccine (at 15-18 months of age) \[Nimenrix 1 Group\] or a fourth dose of Menhibrix vaccine (at 12-15 months of age) and 1 dose of Infanrix vaccine (at 15-18 months of age) \[Menhibrix 2 Group\], or 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine (at 15-18 months of age) \[Nimenrix 2 Group\].
- ActHIB- Infanrix Group (Type: ACTIVE_COMPARATOR): Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age and 1 booster dose of Infanrix vaccine at 15-18 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete